biostudies-literatureUnknown33(9)Bays HE<h4>Objective</h4>To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.<h4>Research design and methods</h4>Post hoc analysis of over 2,000 metabolic syndrome patients administered either FA + low- or moderate-dose statin; FA alone; or low-, moderate-, or high-dose statin alone.<h4>Results</h4>FA + low- or moderate-dose statin combination therapy reduced the presence of metabolic syndrome (35.7 or 35.9%, respectively) more than low-, moderate-, or high-dose statin monotherapy (15.5, 16.6, or 13.8%, respectively), mostly due to improvements in triglycerides and HDL cholesterol levels. Mean glucose levels slightly decreased with FA monotherapy, slightly increased with statin monotherapy, and were essentially unchanged with FA + statin. FA with or without statin also reduced non-HDL cholesterol, apolipoprotein B, total cholesterol, VLDL cholesterol, and high-sensitivity C-reactive protein.<h4>Conclusions</h4>FA + statin in patients with mixed dyslipidemia reduces the prevalence of metabolic syndrome.Diabetes care2113-6https://www.ebi.ac.uk/biostudies/studies/S-EPMC2928374biostudies-literatureThe effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.PMC2928374Sleep DJMcKenney JMSetze CMThakker KMObermeyer KKelly MTBays HERoth EMfalseThe effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.<h4>Objective</h4>To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.<h4>Research design and methods</h4>Post hoc analysis of over 2,000 metabolic syndrome patients administered either FA + low- or moderate-dose statin; FA alone; or low-, moderate-, or high-dose statin alone.<h4>Results</h4>FA + low- or moderate-dose statin combination therapy reduced the presence of metabolic syndrome (35.7 or 35.9%, respectively) more than low-, moderate-, or high-dose statin monotherapy (15.5, 16.6, or 13.8%, respectively), mostly due to improvements in triglycerides and HDL cholesterol levels. Mean glucose levels slightly decreased with FA monotherapy, slightly increased with statin monotherapy, and were essentially unchanged with FA + statin. FA with or without statin also reduced non-HDL cholesterol, apolipoprotein B, total cholesterol, VLDL cholesterol, and high-sensitivity C-reactive protein.<h4>Conclusions</h4>FA + statin in patients with mixed dyslipidemia reduces the prevalence of metabolic syndrome.2010-01-01T00:00:00Z2010 Sep2024-11-06T16:15:52.215Z2019-03-27T00:33:34ZS-EPMC29283742057375010.2337/dc10-0357